News Archive

Patients who experienced Type 2 myocardial infarction were older and more likely to have comorbidities and risk factors than those who experienced Type 1.

The DCRI served as the statistical and data coordinating center for ISCHEMIA, a late-breaking clinical trial that indicated invasive heart procedures may not reduce the chance of experiencing a maj

By enrolling 8,500 high-risk patients with a recent atherosclerotic cardiovascular disease event, cvMOBIUS will be the first large-scale registry to evaluate real-world lipid management and the effectiveness of PCSK9 inhibitors.

No single stakeholder can successfully address the challenges in clinical research.

A DCRI-led pragmatic clinical trial is focusing on improving quality initiatives so that patients with heart failure receive better care and spend less time in the hospital.

The DCRI’s Robert Mentz, MD, is the co-principal investigator for a pragmatic clinical trial on heart failure called TRANSFORM-HF, which is funded by the National Heart, Lung, and Blood Institute (NHLBI). Mentz discussed features of the trial with Patrice Desvigne-Nickens, MD, a medical officer in the Heart Failure and Arrhythmias Branch of the NHLBI and project officer for TRANSFORM-HF.

The ADAPTABLE study has a diverse team of Adaptors, led and coordinated by the Heart Research Alliance at the University of California, San Francisco, that serve as patient partners and provide insight on all aspects of the study. Schuyler Jones, MD, co-principal investigator of ADAPTABLE, spoke with two Adaptors, Nadine Zemon and Greg Merritt, to discuss their experience and the importance of stakeholder engagement.

The DCRI is working to develop the science behind the best way to say thank you.

The DCRI’s mission is to translate knowledge gained from research into clinical practice in order to improve patient outcomes.

As the DCRI’s Clinical Events Classification (CEC) group grows, its leaders are seeking innova